The BRINP1 (BMP/RA-Inducible Neural-Specific Protein 1) antibody is a tool used to detect and study the BRINP1 protein, a member of the BRINP family implicated in neural development and disease. BRINP1. also known as FAM5C, is a neural-specific protein initially identified as a downstream target of bone morphogenetic protein (BMP) and retinoic acid (RA) signaling pathways. It is highly expressed in the brain, particularly in neurons, and plays roles in regulating cell cycle exit, neuronal differentiation, and synaptic plasticity. Structurally, BRINP1 contains conserved domains like the KY domain, which may mediate protein-protein interactions.
Research using BRINP1 antibodies has linked this protein to neurodevelopmental and psychiatric disorders. Altered BRINP1 expression is observed in schizophrenia, autism spectrum disorders, and Alzheimer's disease, suggesting its involvement in synaptic dysfunction or neurodegeneration. Additionally, BRINP1 has been studied in cancer contexts, where its dysregulation correlates with tumor progression in gliomas and other malignancies.
The BRINP1 antibody enables applications such as Western blotting, immunohistochemistry, and immunofluorescence to map its expression patterns, quantify protein levels, or investigate interactions in cellular models. Validated antibodies typically target specific epitopes, ensuring specificity for human, mouse, or rat BRINP1 homologs. Ongoing studies aim to clarify its molecular mechanisms, including potential roles in apoptosis inhibition or extracellular matrix remodeling, highlighting its therapeutic and diagnostic potential.